Tanios Bekaii-Saab, MD, FACP is a Professor of Medicine at the Mayo Clinic College of Medicine and Science, Leader of the Gastrointestinal Cancer Program at the Mayo Clinic Cancer Center, Medical Director of the Cancer Clinical Research Office, Vice Chair and Section Chief for Medical Oncology for the Division of Hematology/Oncology in the Department of Internal Medicine at the Mayo Clinic in Phoenix, Arizona, USA. He is also the consortium chair for the ACCRU research Network and the clinical research co-lead for the MCCC transformation leadership team for the Mayo Enterprise. Additionally, Dr. Bekaii-Saab is the Mayo Clinic member for the NCCN Guidelines Steering Committee. Dr. Bekaii-Saab is currently the co-leader of the Hepatobiliary Cancer Sub-Committee of the Alliance for Clinical Trials in Oncology and the Vice-Chair for the National Cancer Institute’s Hepatobiliary Task Force. He is also a member of the ASCO Scientific Program Committee for Colorectal and Anal Cancers. Dr. Bekaii-Saab earned his medical degree from the American University of Beirut in Lebanon and completed a residency in internal medicine at Indiana University Medical Center in Indianapolis, Indiana, USA. He then completed fellowships in clinical pharmacology and experimental therapeutics and hematology/oncology at Tufts University/New England Medical Center in Boston, Massachusetts, USA. Dr. Bekaii-Saab, MD, conducts clinical and translational research focused on developing anticancer agents for patients with gastrointestinal cancers. Dr. Bekaii-Saab collaborates extensively with various scientists and industry partners to design and execute innovative clinical trials, including many first-in-human studies. Bekaii-Saab’s research includes a large focus on the incorporation of agents that target the multiple facets of cancer, including genetic and epigenetic drivers, as well as the feeding microenvironment and the immune milieu. His work includes two recent discoveries as co-inventor of a molecule that targets cancer-related cachexia (AR-42) and an anti-PD-1 vaccine (PD-Vaxx), which has resulted in licensing opportunities. Additionally, Dr. Bekaii-Saab’s research has also led to the launch of a number of phase II and III clinical trials, including but not limited to a recent trial with a cancer stem cell inhibitor in pancreatic cancer, the development of an FGFR inhibitor in bile duct cancers, and a contribution to the pivotal study that led to the regulatory approval of nanoliposomal irinotecan for treating pancreatic cancer. Dr. Bekaii-Saab served as a reviewer for many high impact journals and sits on the editorial board of the prestigious Journal of the National Cancer Institute. Dr. Bekaii-Saab has authored or co-authored more than 350 peer reviewed publications, abstracts, and book chapters, including papers in such journals as Lancet, Lancet Oncology, Journal of Clinical Oncology, JAMA, Journal of the National Cancer Institute, Annals of Oncology, and Clinical Cancer Research.